Qualigen Therapeutics, Inc. announced that it has engaged Professor Stephen Neidle as a scientific advisor. Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the Company's in-licensed genomic quadruplex (G4)-selective transcription inhibitor platform. Qualigen is developing this platform's lead compound, now called QN-302, as a potential treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.269 USD | -1.54% | -11.80% | -51.09% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.09% | 1.72M | |
+42.42% | 58.06B | |
-5.82% | 40.53B | |
+37.52% | 38.99B | |
+13.87% | 26.7B | |
-12.56% | 26.56B | |
-21.68% | 18.98B | |
-0.82% | 12.17B | |
+23.89% | 12B | |
+25.08% | 11.92B |
- Stock Market
- Equities
- QLGN Stock
- News Qualigen Therapeutics, Inc.
- Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302